ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA filed a 6-K with a press release on June 27, 2024. Details inside.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 27, 2024, to report a press release dated June 27, 2024. The filing does not contain specific financial figures or operational details beyond the announcement of the press release itself.
Why It Matters
This filing indicates that ImmunoPrecise Antibodies Ltd. has made a new announcement available to the public, which may contain important updates for investors.
Risk Assessment
Risk Level: low — This filing is primarily procedural, reporting the issuance of a press release without disclosing new material financial or operational information.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the 6-K report
- June 27, 2024 (date) — Date of the press release and filing
- Kristin Taylor (person) — Signatory for the filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by ImmunoPrecise Antibodies Ltd. on June 27, 2024.
What is the Commission File Number for ImmunoPrecise Antibodies Ltd.?
The Commission File Number for ImmunoPrecise Antibodies Ltd. is 001-39530.
When was the press release mentioned in the filing dated?
The press release mentioned in the filing is dated June 27, 2024.
Who signed the Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed the Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.
Does this filing contain specific financial results or operational updates?
No, this filing primarily serves to report the issuance of a press release and does not contain specific financial results or detailed operational updates within the 6-K document itself.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-06-27 09:03:41
Filing Documents
- press_release_june_27_20.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 11KB
- 0000950170-24-078181.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: June 27, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer